CSPG4 and acute lymphoblastic leukemia: Using robust preclinical patient-derived xenograft (PDX) models, we show that NG2 antagonists synergize with VxL-based induction therapy, leading to an extensive mobilization of MLLr-B-ALL blasts from bone marrow (BM) into peripheral blood (PB) where they become more accessible/sensitive to VxL-based chemotherapy, resulting in higher CR rates (CRRs), and consequently, higher EFS and delayed time to relapse.